Montesano, G;
Garway-Heath, DF;
Rabiolo, A;
De Moraes, CG;
Ometto, G;
Crabb, DP;
(2023)
Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma.
Translational Vision Science and Technology
, 12
(10)
, Article 20. 10.1167/tvst.12.10.20.
Preview |
PDF
i2164-2591-12-10-20_1698670642.2296.pdf - Published Version Download (847kB) | Preview |
Abstract
Purpose: The purpose of this study was to evaluate the power of trend-based visual field (VF) progression end points against long-term development of event-based end points accepted by the US Food and Drug Administration (FDA). Methods: One eye from 3352 patients with ≥10 24-2 VFs (median = 11 years) follow-up were analyzed. Two FDA-compatible criteria were applied to these series to label “true-progressed” eyes: ≥5 locations changing from baseline by more than 7 dB (FDA-7) or by more than the expected test-retest variability (GPA-like) in 2 consecutive tests. Observed rates of progression (RoP) were used to simulate trial-like series (2 years) randomly assigned (1000 times) to a “placebo” or a “treatment” arm. We simulated neuroprotec-tive “treatment” effects by changing the proportion of “true progressed” eyes in the two arms. Two trend-based methods for mean deviation (MD) were assessed: (1) linear mixed model (LMM), testing average difference in RoP between the two arms, and (2) time-to-progression (TTP), calculated by linear regression as time needed for MD to decline by predefined cutoffs from baseline. Power curves with 95% confidence intervals were calculated for trend and event-based methods on the simulated series. Results: The FDA-7 and GPA-like progression was achieved by 45% and 55% of the eyes in the clinical database. LMM and TTP had similar power, significantly superior to the event-based methods, none of which reached 80% power. All methods had a 5% false-positive rate. Conclusions: The trend-based methods can efficiently detect treatment effects defined by long-term FDA-compatible progression. Translational Relevance: The assessment of the power of trend-based methods to detect clinically relevant progression end points.
| Type: | Article |
|---|---|
| Title: | Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1167/tvst.12.10.20 |
| Publisher version: | https://doi.org/10.1167/tvst.12.10.20 |
| Language: | English |
| Additional information: | Copyright © 2023 The Authors. This work is licensed under a Creative Commons Attribution 4.0 International License. |
| Keywords: | Humans, Eye, Glaucoma, Neuroprotection, United States, Visual Fields, Randomized Controlled Trials as Topic |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10183813 |
Archive Staff Only
 |
View Item |
